Thomas H. Pillow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Thomas H. Pillow has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
- Gail Lewis Phillips
Genentech
20 shared publications - Alex Uttard
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Bingfan Du
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - David H. Lee
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Dokyong Kim
Mersana Therapeutics, Cambridge, Massachusetts
19 shared publications - Dorin Toader
Mersana Therapeutics, Inc., Cambridge, Massachusetts
19 shared publications
Latest Publications
- 2 June 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
Characterizing Antibody-Drug Conjugates with High Molecular Heterogeneity by Native Direct Mass Technology
Mass spectrometry (MS) has emerged as a powerful tool for characterizing antibody-drug conjugates (ADCs), enabling the determination of the drug-to-antibody ratio (DAR) and the monitoring of ADC degradation. Here we present a native direct mass technology (DMT) approach, an Orbitrap-based charge detection MS integrated with the SampleStream platform and Newomics' MnESI source, providing automated, highly sensitive analysis of DAR and stability for two interchain-modified high DAR ADCs (DAR 14) in native conditions. We applied this platform to samples from formulation buffer, as well as from ex vivo and in vivo conditions, where ADC concentrations were substantially lower. Owing to the pronounced heterogeneity of these DAR-14 ADCs, direct DAR characterization was only achievable using native DMT, underscoring the limitations of conventional native MS in studying heterogeneous ADCs. Furthermore, the interchain stability assessments from biomatrices demonstrate that native DMT delivers a robust, high-resolution method for characterizing interchain-modified high DAR ADCs across diverse biological environments.
- 2 June 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
Characterizing Antibody-Drug Conjugates with High Molecular Heterogeneity by Native Direct Mass Technology
Mass spectrometry (MS) has emerged as a powerful tool for characterizing antibody-drug conjugates (ADCs), enabling the determination of the drug-to-antibody ratio (DAR) and the monitoring of ADC degradation. Here we present a native direct mass technology (DMT) approach, an Orbitrap-based charge detection MS integrated with the SampleStream platform and Newomics' MnESI source, providing automated, highly sensitive analysis of DAR and stability for two interchain-modified high DAR ADCs (DAR 14) in native conditions. We applied this platform to samples from formulation buffer, as well as from ex vivo and in vivo conditions, where ADC concentrations were substantially lower. Owing to the pronounced heterogeneity of these DAR-14 ADCs, direct DAR characterization was only achievable using native DMT, underscoring the limitations of conventional native MS in studying heterogeneous ADCs. Furthermore, the interchain stability assessments from biomatrices demonstrate that native DMT delivers a robust, high-resolution method for characterizing interchain-modified high DAR ADCs across diverse biological environments.
- Open Access
- 3 April 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (4) , 652-661
Mechanistic Characterization of the Potency of THIOMAB Antibody–Drug Conjugates Targeting Staphylococcus aureus and ETbR-Expressing Tumor Cells Using Quantitative LC-MS/MS Analysis of Intracellular Drug Accumulation
THIOMAB drug conjugate (TDC) technology provides site-specific conjugation of linker drugs to antibodies, allowing for targeted delivery of the payload. While a direct measurement of TDC cytotoxic potency allows efficient screening and confirmation that new drugs conjugated to antibodies result in proper processing in cells, additional mechanistic characterization is often needed to provide information-rich data to guide further optimization of TDC design. For example, a quantitative understanding of how TDCs are processed intracellularly can help determine which processing step is impacting payload delivery and thereby inform the basis of the TDC efficacy. Here, we measure the cellular accumulation of two different TDC drug payloads: MAPK (mitogen-activated protein kinase) pathway inhibitor targeting ETbR-expressing tumor cells and an antibiotic active against Staphylococcus aureus with an in vitro cell-based drug release LC-MS/MS assay in a 96-well format. This assay allowed us to correlate the cellular potency of each unconjugated molecule with the amount of payload that accumulated inside the cell. In the case of the pathway inhibitor drug, the biochemical characterization of TDC processing by cathepsin B and purified human liver enzyme extract demonstrated a correlation between the efficiency of the linker drug cleavage and intracellular payload accumulation. For the antibody-antibiotic conjugate, kinetic analysis of intracellular free drug retention provided valuable insight into the chemistry modifications needed for an efficient TDC. Taken together, we demonstrated the utility of quantitative LC-MS/MS assays as one tool in guiding the design of more effective TDCs via the mechanistic release characterization of two distinct payloads.
- 3 April 2025
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 36 (4) , 652-661
Open AccessMechanistic Characterization of the Potency of THIOMAB Antibody–Drug Conjugates Targeting Staphylococcus aureus and ETbR-Expressing Tumor Cells Using Quantitative LC-MS/MS Analysis of Intracellular Drug Accumulation
THIOMAB drug conjugate (TDC) technology provides site-specific conjugation of linker drugs to antibodies, allowing for targeted delivery of the payload. While a direct measurement of TDC cytotoxic potency allows efficient screening and confirmation that new drugs conjugated to antibodies result in proper processing in cells, additional mechanistic characterization is often needed to provide information-rich data to guide further optimization of TDC design. For example, a quantitative understanding of how TDCs are processed intracellularly can help determine which processing step is impacting payload delivery and thereby inform the basis of the TDC efficacy. Here, we measure the cellular accumulation of two different TDC drug payloads: MAPK (mitogen-activated protein kinase) pathway inhibitor targeting ETbR-expressing tumor cells and an antibiotic active against Staphylococcus aureus with an in vitro cell-based drug release LC-MS/MS assay in a 96-well format. This assay allowed us to correlate the cellular potency of each unconjugated molecule with the amount of payload that accumulated inside the cell. In the case of the pathway inhibitor drug, the biochemical characterization of TDC processing by cathepsin B and purified human liver enzyme extract demonstrated a correlation between the efficiency of the linker drug cleavage and intracellular payload accumulation. For the antibody-antibiotic conjugate, kinetic analysis of intracellular free drug retention provided valuable insight into the chemistry modifications needed for an efficient TDC. Taken together, we demonstrated the utility of quantitative LC-MS/MS assays as one tool in guiding the design of more effective TDCs via the mechanistic release characterization of two distinct payloads.
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Data File 1 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Complete synthetic route for Monomeric Dolasynthen linker-scaffold-payload
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S3 shows body weights of animals at two doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S3 shows body weights of animals at two doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S4 compares the nominal DAR to the calculated DAR values from measured Cmax values for each ADC
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S4 compares the nominal DAR to the calculated DAR values from measured Cmax values for each ADC
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S2 shows a graphical representation of IC50 spread over range of cytotoxicity experiments
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Table S3 contains response numbers for in vivo efficacy study
- Open Access
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses
- 3 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Site-Specific Dolasynthen Antibody–Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody Ratios
Figure S4 compares the body weights of mice dosed with DAR2 and DAR18 ADCs at matched payload and antibody doses